Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | 10% owner | October 06, 2020 | October 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date October 06, 2020 · Filed October 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 882,475 |
Reported balance
After 2020-10-06 transaction · row 1
1 source rowRow 1 · 2020-10-06 · Conversion · Acquired 882,475 · Balance 882,475 F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 38,464 |
Reported balance
After 2020-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-06 · Conversion · Acquired 38,464 · Balance 38,464 F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-06 · Conversion · Disposed 882,475 · Balance 0 F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-06 · Conversion · Disposed 38,464 · Balance 0 F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2023-06-02 | Direct | 0 |
Reported balance
After 2020-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-06 · Conversion · Disposed 111,111 · Balance 0 F3: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4: Immediately exercisable. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2023-06-02 | Direct | 111,111 |
Reported balance
After 2020-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-06 · Conversion · Acquired 111,111 · Balance 111,111 F3: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
F2: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation.
F3: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
F4: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 111,111 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · derivative · entry 6 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,111 Underlying: Common Stock · 111,111 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 111,111 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · derivative · entry 5 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series A Convertible Preferred Stock · 111,111 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionSeries A Convertible Preferred Stock · Derivative | 38,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · derivative · entry 4 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 38,464 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionSeries A Convertible Preferred Stock · Derivative | 882,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · derivative · entry 3 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 882,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionCommon Stock | 38,464 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · nonDerivative · entry 2 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 18:14 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionCommon Stock | 882,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054317 · doc4.xml · nonDerivative · entry 1 MORRIS I WISTAR III · CIK 0000898242 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.